Effects of Recombinant Erythropoietin on Breast Cancer-initiating Cells

Overview

Journal Neoplasia

Publisher Elsevier

Specialty Oncology

Date 2007 Dec 18

PMID 18084619

Citations 37

Authors

Tiffany M Phillips

Kwanghee Kim

Erina Vlashi

William H McBride

Frank Pajonk

Affiliations

Soon will be listed here.

Abstract

Background: Cancer anemia causes fatigue and correlates with poor treatment outcome. Erythropoietin has been introduced in an attempt to correct these defects. However, five recent clinical trials reported a negative impact of erythropoietin on survival and/or tumor control, indicating that experimental evaluation of a possible direct effect of erythropoietin on cancer cells is required. Cancer recurrence is thought to rely on the proliferation of cancer initiating cells (CICs). In breast cancer, CICs can be identified by phenotypic markers and their fate is controlled by the Notch pathway.

Methods: In this study, we investigated the effect of erythropoietin on CICs in breast cancer cell lines. Levels of erythropoietin receptor (EpoR), CD24, CD44, Jagged-1 expression, and activation of Notch-1 were assessed by flow cytometry. Self-renewing capacity of CICs was investigated in sphere formation assays.

Results: EpoR expression was found on the surface of CICs. Recombinant human Epo (rhEpo) increased the numbers of CICs and self-renewing capacity in a Notch-dependent fashion by induction of Jagged-1. Inhibitors of the Notch pathway and PI3-kinase blocked both effects.

Conclusions: Erythropoietin functionally affects CICs directly. Our observation may explain the negative impact of recombinant Epo on local control and survival of cancer patients with EpoR-positive tumors.

Citing Articles

Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer.

Shen Q, Murakami K, Sotov V, Butler M, Ohashi P, Reedijk M Sci Adv. 2024; 10(44):eado8275.

PMID: 39475614 PMC: 11524187. DOI: 10.1126/sciadv.ado8275.

Novel Anti-Cancer Stem Cell Compounds: A Comprehensive Review.

Guo S, Zheng S, Liu M, Wang G Pharmaceutics. 2024; 16(8.

PMID: 39204369 PMC: 11360402. DOI: 10.3390/pharmaceutics16081024.

Recurrent Conjunctival Squamous Cell Carcinoma and Intraocular Tumor Extension after Topical Erythropoietin: A Case Report.

Feizi S, Esfandiari H Case Rep Ophthalmol. 2022; 13(1):89-95.

PMID: 35350235 PMC: 8921966. DOI: 10.1159/000521735.

Notch Signaling in Vascular Endothelial Cells, Angiogenesis, and Tumor Progression: An Update and Prospective.

Akil A, Gutierrez-Garcia A, Guenter R, Rose J, Beck A, Chen H Front Cell Dev Biol. 2021; 9:642352.

PMID: 33681228 PMC: 7928398. DOI: 10.3389/fcell.2021.642352.

Unlocking the Secrets of Cancer Stem Cells with γ-Secretase Inhibitors: A Novel Anticancer Strategy.

Ghanbari-Movahed M, Ghanbari-Movahed Z, Momtaz S, Kilpatrick K, Farzaei M, Bishayee A Molecules. 2021; 26(4).

PMID: 33673088 PMC: 7917912. DOI: 10.3390/molecules26040972.

References

Sheridan C, Kishimoto H, Fuchs R, Mehrotra S, Bhat-Nakshatri P, Turner C . CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006; 8(5):R59. PMC: 1779499. DOI: 10.1186/bcr1610. View

Phillips T, McBride W, Pajonk F . The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006; 98(24):1777-85. DOI: 10.1093/jnci/djj495. View

Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-8. PMC: 153034. DOI: 10.1073/pnas.0530291100. View

Henke M, Laszig R, Rube C, Schafer U, Haase K, Schilcher B . Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003; 362(9392):1255-60. DOI: 10.1016/S0140-6736(03)14567-9. View

Collins A, Berry P, Hyde C, Stower M, Maitland N . Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005; 65(23):10946-51. DOI: 10.1158/0008-5472.CAN-05-2018. View

Henke M, Mattern D, Pepe M, Bezay C, Weissenberger C, Werner M . Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J Clin Oncol. 2006; 24(29):4708-13. DOI: 10.1200/JCO.2006.06.2737. View

Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D . Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005; 65(13):5506-11. DOI: 10.1158/0008-5472.CAN-05-0626. View

Digicaylioglu M, Garden G, Timberlake S, Fletcher L, Lipton S . Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I. Proc Natl Acad Sci U S A. 2004; 101(26):9855-60. PMC: 470763. DOI: 10.1073/pnas.0403172101. View

Woodward W, Chen M, Behbod F, Alfaro M, Buchholz T, Rosen J . WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A. 2007; 104(2):618-23. PMC: 1766434. DOI: 10.1073/pnas.0606599104. View

10.

Dontu G, Abdallah W, Foley J, Jackson K, Clarke M, Kawamura M . In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003; 17(10):1253-70. PMC: 196056. DOI: 10.1101/gad.1061803. View

11.

Thews O, Koenig R, Kelleher D, Kutzner J, Vaupel P . Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer. 1998; 78(6):752-6. PMC: 2062974. DOI: 10.1038/bjc.1998.572. View

12.

Siemers E, Quinn J, Kaye J, Farlow M, Porsteinsson A, Tariot P . Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology. 2006; 66(4):602-4. DOI: 10.1212/01.WNL.0000198762.41312.E1. View

13.

Lacroix M, Leclercq G . Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat. 2004; 83(3):249-89. DOI: 10.1023/B:BREA.0000014042.54925.cc. View

14.

Ribatti D, Marzullo A, Nico B, Crivellato E, Ria R, Vacca A . Erythropoietin as an angiogenic factor in gastric carcinoma. Histopathology. 2003; 42(3):246-50. DOI: 10.1046/j.1365-2559.2003.01581.x. View

15.

Bittorf T, Buchse T, Sasse T, Jaster R, Brock J . Activation of the transcription factor NF-kappaB by the erythropoietin receptor: structural requirements and biological significance. Cell Signal. 2001; 13(9):673-81. DOI: 10.1016/s0898-6568(01)00189-9. View

16.

Chen M, Woodward W, Behbod F, Peddibhotla S, Alfaro M, Buchholz T . Wnt/beta-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line. J Cell Sci. 2007; 120(Pt 3):468-77. DOI: 10.1242/jcs.03348. View

17.

Carvalho G, Lefaucheur C, Cherbonnier C, Metivier D, Chapel A, Pallardy M . Chemosensitization by erythropoietin through inhibition of the NF-kappaB rescue pathway. Oncogene. 2004; 24(5):737-45. DOI: 10.1038/sj.onc.1208205. View

18.

Acs G, Zhang P, Rebbeck T, Acs P, Verma A . Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer. 2002; 95(5):969-81. DOI: 10.1002/cncr.10787. View

19.

Frommhold H, Guttenberger R, Henke M . The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience. Strahlenther Onkol. 1999; 174 Suppl 4:31-4. View

20.

Bash J, Zong W, Banga S, Rivera A, Ballard D, Ron Y . Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors. EMBO J. 1999; 18(10):2803-11. PMC: 1171361. DOI: 10.1093/emboj/18.10.2803. View